Amr El Dorado — research payments reported

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$20,078	124
2024	Research	$26,166	4
2023	Research	$130,312	4

Breakdown

Who paid Research payments · program years 2023–2025

Vertex Pharmaceuticals Incorporated $128,693 2 payments
Boehringer Ingelheim International GmbH $25,969 119 payments
Boehringer Ingelheim Pharma GmbH & Co.KG $10,015 3 payments
Moderna TX, Inc. $6,887 3 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $4,991 5 payments

Studies the money was for Research payments · program years 2023–2025

Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN) $128,693 2 payments
Obesity Long term safety in patients with CV risk $20,923 4 payments
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. $11,316 16 payments
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD $8,736 107 payments
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 $6,862 2 payments
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants $26 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.